DCPH Deciphera Pharmaceuticals Inc.

48.59
+1.12  (+2%)
Previous Close 47.47
Open 47.33
Price To Book 4.1
Market Cap 2,480,223,684
Shares 51,043,912
Volume 706,311
Short Ratio
Av. Daily Volume 511,718
Stock charts supplied by TradingView

NewsSee all news

  1. Deciphera Pharmaceuticals, Inc. Announces Third Quarter 2019 Financial Results

    - Ripretinib Granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA) for the Treatment of Patients with Advanced Gastrointestinal Stromal Tumors (GIST) - - Clinical Progress Across

  2. Deciphera Pharmaceuticals Presents Updated Data from Ripretinib and DCC-3014 Programs at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

    - Median Progression Free Survival (mPFS) of 46 Weeks for the Second-Line Gastrointestinal Stromal Tumors (GIST) Cohort from the Phase 1 Study of Ripretinib in Patients Receiving 150 mg QD as Starting Dose - -

  3. Deciphera Pharmaceuticals Presents Data from Rebastinib and DCC-3116 Programs at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

    - Combination of Rebastinib and Paclitaxel Exhibited Encouraging Preliminary Anti-tumor Activity Across Treatment Arms in the Ongoing Phase 1b/2 Clinical Study - - DCC-3116 Represents a Differentiated Approach to

  4. Deciphera Pharmaceuticals, Inc. to Announce Third Quarter 2019 Financial Results and Host Conference Call and Webcast on November 4, 2019

    Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced that it will report its third quarter 2019

  5. Deciphera Pharmaceuticals Appoints Matthew L. Sherman, M.D. as Executive Vice President and Chief Medical Officer

    Accomplished CMO Brings Deep Clinical Drug Development Expertise from Leading Biotech and Pharma Companies Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company addressing key

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1 initial TGCT data to be presented at CTOS Meeting November 13-16, 2019.
DCC-3014
Solid tumors or hematological malignancies
NDA filing due 1Q 2020.
Ripretinib DCC-2618 - INVICTUS
Gastrointestinal Stromal Tumors (GIST) - fourth-line
Phase 3 trial initiation announced December 20, 2018.
DCC-2618 - INTRIGUE
Gastrointestinal Stromal Tumors (GIST) - second-line
Phase 1b trial complete.
Rebastinib
Breast Cancer
Phase 1b/2 preliminary data noted 8/43 partial responses - October 28, 2019.
Rebastinib and paclitaxel
Solid tumors
Phase 1b/2 trial initiation announced January 3, 2019.
Rebastinib and carboplatin
Solid tumors
Phase 1 updated data presented at AACR-NCI-EORTC October 29, 2019.
Ripretinib DCC-2618
Gastrointestinal Stromal Tumors (GIST) - second-fourth line

Latest News

  1. Deciphera Pharmaceuticals, Inc. Announces Third Quarter 2019 Financial Results

    - Ripretinib Granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA) for the Treatment of Patients with Advanced Gastrointestinal Stromal Tumors (GIST) - - Clinical Progress Across

  2. Deciphera Pharmaceuticals Presents Updated Data from Ripretinib and DCC-3014 Programs at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

    - Median Progression Free Survival (mPFS) of 46 Weeks for the Second-Line Gastrointestinal Stromal Tumors (GIST) Cohort from the Phase 1 Study of Ripretinib in Patients Receiving 150 mg QD as Starting Dose - -

  3. Deciphera Pharmaceuticals Presents Data from Rebastinib and DCC-3116 Programs at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

    - Combination of Rebastinib and Paclitaxel Exhibited Encouraging Preliminary Anti-tumor Activity Across Treatment Arms in the Ongoing Phase 1b/2 Clinical Study - - DCC-3116 Represents a Differentiated Approach to

  4. Deciphera Pharmaceuticals, Inc. to Announce Third Quarter 2019 Financial Results and Host Conference Call and Webcast on November 4, 2019

    Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced that it will report its third quarter 2019

  5. Deciphera Pharmaceuticals Appoints Matthew L. Sherman, M.D. as Executive Vice President and Chief Medical Officer

    Accomplished CMO Brings Deep Clinical Drug Development Expertise from Leading Biotech and Pharma Companies Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company addressing key

  6. Deciphera Pharmaceuticals Announces Late-Breaking Oral Presentation at the ESMO 2019 Congress Demonstrating Positive Results from INVICTUS Pivotal Phase 3 Study of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumors

    Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company addressing key mechanisms of tumor drug resistance, today announced the late-breaking presentation of results from the INVICTUS

  7. Deciphera Pharmaceuticals, Inc. to Present at the 2019 Cantor Global Healthcare Conference

    Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced that Steve Hoerter, President and Chief Executive

  8. Deciphera Pharmaceuticals Announces Late-Breaking Oral Presentation of Pivotal Phase 3 INVICTUS Data at the European Society for Medical Oncology (ESMO) 2019 Congress

    Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced that data from the Company's INVICTUS pivotal

  9. Deciphera Pharmaceuticals Announces Full Exercise of Underwriters' Option to Purchase Additional Shares in Public Offering of Common Stock

    Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced that the underwriters of its previously announced